Incyte Q4 Adj EPS Misses Estimates, But Revenues Top

RTTNews | 623 days ago
Stocktwits
Incyte Q4 Adj EPS Misses Estimates, But Revenues Top

(RTTNews) - Incyte Corp. (INCY) on Tuesday reported net income of $201.10 million or $0.89 per share for the fourth quarter, sharply higher than $28.46 million or $0.13 per share in the prior-year quarter.

Excluding items, adjusted net income for the quarter was $1.06 per share, compared to $0.62 per share in the year-ago quarter.

Total revenues for the quarter rose 9 percent to $1.01 billion from $926.70 million in the same quarter last year.

On average, analysts polled by Thomson Reuters expected the company to report earnings of $1.16 per share on revenues of $1.0 billion for the quarter. Analysts' estimates typically exclude special items.

Looking ahead to fiscal 2024, Incyte now projects Jakafi net product revenue in a range of $2.69 billion to $2.75 billion. Other Hematology/Oncology net product revenues are projected between $325 million and $360 million.

For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com

Tags: INCY
Stocktwits
read more
Incyte Says FDA Issued CRL For Ruxolitinib Extended-release Tablets

Incyte Says FDA Issued CRL For Ruxolitinib Extended-release Tablets

Incyte Corp. (INCY) announced Friday that the U.S. Food and Drug Administration (FDA) has issued a complete response letter for ruxolitinib extended-release (XR) tablets, a JAK1/JAK2 inhibitor, for once-daily (QD) use in the treatment of certain types of myelofibrosis (MF), polycythemia vera (PV) and graft-versus-host disease (GVHD).
RTTNews | 949 days ago
Incyte Q1 Results Top Estimates

Incyte Q1 Results Top Estimates

Incyte Corp. (INCY) on Tuesday reported net income of $161.43 million or $0.72 per share for the first quarter, up from $149.46 million or $0.67 per share in the prior-year quarter.
RTTNews | 1183 days ago
Mild Upside Anticipated For Japan Stock Market

Mild Upside Anticipated For Japan Stock Market

The Japan stock market on Tuesday ended the two-day winning streak in which it had rallied more than 1,800 points or 3 percent. The Nikkei 225 now rests just shy of the 50,220-point plateau although it's likely to bounce higher again on Wednesday.
RTTNews | 14 minutes ago
Renewed Support Seen For KOSPI

Renewed Support Seen For KOSPI

The South Korea stock market on Tuesday ended the wo-day winning streak in which it had gained almost 200 points or 5 percent on its way to a fresh record closing high. The KOSPI now sits just above the 4,010-point plateau and it's expected to tick higher again on Wednesday.
RTTNews | 29 minutes ago
Tools
Economic Calendar
Market Hours
Interest Rates
Holidays Calendar
Forex Market
Forex Volatility
Forex Correlation
Forex News
Forex analysis
COT Data
Liquidity
Forex Calculators
Forex Heat Map
Economic Indicators
Community
Community
Systems
Most Popular Systems
Strategies
Contests
Forex Charts
Forex Sentiment
Sentiment Indicator
Reviews
Brokers
Prop Trading Firms
VPS Services
Signal Providers
EA Programming Services
Affiliate Programs
PAMM Broker Services
Rebate Program Services
Trading Platforms
Expert Advisors
Crypto Exchanges
Trading courses
Brokers
Forex Spreads
Forex Broker Quotes
Forex Broker Swaps
Forex Broker Volume
Forex Broker Promotions
Press Release
Platform
Widgets
Features
API
RSS
Stock Portfolio
Affiliate Software
Advanced Charts
Support
FAQ
Help
Contact Us
Report a Bug!
About
Blog
© 2025 Myfxbook Ltd. All Rights Reserved.
HIGH RISK WARNING: Foreign exchange trading carries a high level of risk that may not be suitable for all investors. Leverage creates additional risk and loss exposure. Before you decide to trade foreign exchange, carefully consider your investment objectives, experience level, and risk tolerance. You could lose some or all of your initial investment. Do not invest money that you cannot afford to lose. Educate yourself on the risks associated with foreign exchange trading, and seek advice from an independent financial or tax advisor if you have any questions. Any data and information is provided 'as is' solely for informational purposes, and is not intended for trading purposes or advice. Past performance is not indicative of future results.